Comprehensive Legal Counsel for Life Sciences and Drug List Inclusion

Within its Life Sciences & Healthcare practice, BRACE Law Firm provides professional legal services to manufacturers and distributors of medicinal products, medical devices, and dietary supplements, as well as other healthcare organizations, on matters of domestic and international law. We deliver comprehensive legal assistance in commercial operations support, dispute resolution and litigation, public and corporate procurement, antitrust law, international trade law, regulatory affairs, and compliance workflows.

A core focus of the legal offerings within the Life Sciences & Healthcare practice at BRACE Law Firm involves providing sophisticated legal support for the inclusion of medicines in statutory drug lists and formularies.

Regulatory Advisory on Listing Medicines in the VED List and Specialized Healthcare Programs

Russian Government Decree No. 871 has approved the rules for forming the Vital and Essential Drugs (VED) List for medical use, as well as the specialized list of medicinal products intended to supply patients with hemophilia, cystic fibrosis, pituitary dwarfism, Gaucher disease, malignant neoplasms of lymphoid, hematopoietic, and related tissues, multiple sclerosis, hemolytic-uremic syndrome, juvenile arthritis with systemic onset, mucopolysaccharidosis types I, II, and VI, and individuals post-organ and/or tissue transplantation (the "High-Cost Nosologies" program). The VED List is compiled based on the International Nonproprietary Names (INNs) of medicinal products satisfying the following statutory criteria:

1. The medicinal product is duly registered in the Russian Federation;
2. The drug is actively utilized for the diagnosis, prevention, treatment, and rehabilitation within medical care for diseases and conditions, including those prevailing in the disease profile of the Russian Federation;
3. The medicinal product demonstrates a distinct therapeutic advantage compared to other drugs when treating a specific disease or clinical condition.

Legal Analysis of Criteria and Feasibility Profiles for Formulary Inclusion

The specialized drug list for the High-Cost Nosologies program is similarly formed based on the INNs of medicinal products satisfying the following criteria:

1. The medicinal product is duly registered in the Russian Federation;
2. The drug is officially included in the active VED List;
3. The medicinal product demonstrates a clear therapeutic advantage compared to alternative drugs when treating patients diagnosed with hemophilia, cystic fibrosis, pituitary dwarfism, Gaucher disease, malignant neoplasms of lymphoid, hematopoietic, and related tissues, multiple sclerosis, hemolytic-uremic syndrome, juvenile arthritis with systemic onset, mucopolysaccharidosis types I, II, and VI, or individuals following organ and/or tissue transplantation.

The specific medicinal products included in the aforementioned lists directly dictate their downstream market circulation parameters and determine their eligibility for certain regulatory advantages during the commercial lifecycle of such drugs.

Dossier Compilation and Submission Management for Statutory Drug Listing

Reviewing the potential inclusion of medicinal products into one of the aforementioned lists requires the formal submission of an application alongside a technical documentation package mandated by the Government of the Russian Federation. However, achieving successful listing requires strict adherence to formal application structures and evidentiary requirements.

Scope of Legal Services for Drug List Optimization and Compliance

1. Delivering strategic advisory support for independent dossier compilation and application formatting;
2. Formulating comprehensive legal opinions regarding the commercial feasibility of formulary inclusion;
3. Handling the end-to-end compilation, verification, and filing of applications along with required evidentiary packages;
4. Representing client interests throughout the regulatory review and evaluation phases before administrative bodies;
5. Navigating regulatory requirements for delisting procedures, conducting legal audits of delisting grounds, and litigating against arbitrary or unlawful forced exclusions from statutory drug lists.